CHC Healthcare Group

TWSE:4164 Stock Report

Market Cap: NT$6.6b

CHC Healthcare Group Valuation

Is 4164 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4164 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4164 (NT$39.8) is trading below our estimate of fair value (NT$45.67)

Significantly Below Fair Value: 4164 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4164?

Key metric: As 4164 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4164. This is calculated by dividing 4164's market cap by their current earnings.
What is 4164's PE Ratio?
PE Ratio20.5x
EarningsNT$324.06m
Market CapNT$6.64b

Price to Earnings Ratio vs Peers

How does 4164's PE Ratio compare to its peers?

The above table shows the PE ratio for 4164 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.6x
1788 Hi-Clearance
16.7xn/aNT$6.2b
4104 Excelsior Medical
18.5xn/aNT$14.2b
4173 Arich Enterprise
19.2xn/aNT$1.5b
3118 Level Biotechnology
15.8xn/aNT$1.0b
4164 CHC Healthcare Group
20.5x68.3%NT$6.6b

Price-To-Earnings vs Peers: 4164 is expensive based on its Price-To-Earnings Ratio (20.5x) compared to the peer average (17.6x).

Price to Earnings Ratio vs Industry

How does 4164's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
4164 20.5xIndustry Avg. 21.4xNo. of Companies46PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4164 is good value based on its Price-To-Earnings Ratio (20.5x) compared to the Asian Healthcare industry average (21.4x).

Price to Earnings Ratio vs Fair Ratio

What is 4164's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4164 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.5x
Fair PE Ratio41.9x

Price-To-Earnings vs Fair Ratio: 4164 is good value based on its Price-To-Earnings Ratio (20.5x) compared to the estimated Fair Price-To-Earnings Ratio (41.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Pacific Hospital Supply

NT$6.4b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$88.40

7D

-0.5%

1Y

5.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

7D

0%

1Y

2.2%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$29.85

7D

-2.0%

1Y

-19.3%